Search

Author/Creator Dubost, Jean‐Jacques

2. Retention rates of adalimumab, etanercept and infliximab as first‐line biotherapy agent for rheumatoid arthritis patients in daily practice ‐ Auvergne experience. (13th September 2017)

Authors:
Soubrier, Martin; Pereira, Bruno; Frayssac, Thomas; Fan, Angelique; Couderc, Marion; Malochet‐Guinamand, Sandrine; Mathieu, Sylvain; Tatar, Zuzana; Tournadre, Anne; Dubost, Jean‐Jacques
Journal:
International journal of rheumatic diseases
Issue:
Volume 21:Number 11(2018)
Page Start:
1924
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France). (30th August 2018)

Authors:
Soubrier, Martin; Pereira, Bruno; Fan, Angelique; Frayssac, Thomas; Couderc, Marion; Malochet‐Guinamand, Sandrine; Mathieu, Sylvain; Tatar, Zuzana; Tournadre, Anne; Dubost, Jean‐Jacques
Journal:
International journal of rheumatic diseases
Issue:
Volume 21:Number 11(2018)
Page Start:
1986
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. The development of a questionnaire to evaluate rheumatoid arthritis patient's knowledge about methotrexate. Issue 5 (2nd November 2015)

Authors:
Fayet, Françoise; Savel, Carine; Rodere, Malory; Pereira, Bruno; Abdi, Dihya; Mathieu, Sylvain; Tournadre, Anne; Soubrier, Martin; Dubost, Jean‐Jacques
Journal:
Journal of clinical nursing
Issue:
Volume 25:Issue 5/6(2016)
Page Start:
682
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗